Evidence mapPaperPMID 41246121Full record

ArticleTouchREVIEWS in endocrinology2025

Advancing the Therapeutic Frontier in Thyroid Eye Disease.

Seyed Omid Mohammadi, Coby Ray

Abstract readEditorial
In one paragraph

Article in TouchREVIEWS in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Seyed Omid MohammadiSchool of Medicine, Texas Christian University, Fort Worth, TX, USA.
Coby RayOphthalmology, Texas Tech University Health Sciences Center, Lubbock, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid eye disease (TED), also known as Graves' orbitopathy, is driven by autoimmune processes that lead to orbital inflammation, oedema and potential vision loss. Traditional management includes high-dose intravenous corticosteroids, orbital radiotherapy and surgery. However, newer therapies, notably teprotumumab (a monoclonal antibody against the insulin-like growth factor I receptor), offer targeted immunomodulation with promising outcomes in reducing proptosis and improving symptoms. The future of TED treatment lies in further research on biologics, personalized approaches and continued multidisciplinary collaboration to optimize patient care.

Indexed as

BactoclimabexophthalmosGraves' ophthalmopathyhyperthyroidisminterleukin-6teprotumumabthyroid eye diseasetumour necrosis factor-alpha

Identifiers

PMID41246121
PMCPMC12616671

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.